Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Telithromycin.

Keri Wellington1, Stuart Noble

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|July 20, 2004
PubMed
Summary
This summary is machine-generated.

Telithromycin, a novel ketolide antibiotic, effectively treats respiratory infections like pneumonia, sinusitis, and bronchitis, including resistant strains. It demonstrates comparable efficacy to other antibiotics with a generally favorable safety profile.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trauma, identity and transition: evaluation of the RESLEAPS programme for retiring senior police officers.

Frontiers in psychiatry·2026
Same author

Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.

Drugs·2007
Same author

Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.

Drugs & aging·2007
Same author

Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.

Drugs·2006
Same author

Insulin glulisine.

Drugs·2006
Same author

Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris.

Drugs·2006
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Respiratory Medicine

Background:

  • Telithromycin is the first ketolide antibacterial agent.
  • It exhibits potent activity against common respiratory pathogens, including drug-resistant Streptococcus pneumoniae.
  • US FDA approval has been granted for specific respiratory tract infections.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of telithromycin in treating community-acquired respiratory infections.
  • To compare telithromycin's effectiveness against established antibiotic regimens.

Main Methods:

  • Clinical trials involving patients with acute bacterial sinusitis (ABS), acute bacterial exacerbations of chronic bronchitis (AECB), and community-acquired pneumonia (CAP).
  • Telithromycin (800 mg once daily) was compared to amoxicillin, clarithromycin, amoxicillin/clavulanic acid, cefuroxime axetil, and trovafloxacin regimens.

Related Experiment Videos

  • Adverse events were systematically recorded and analyzed.

    • Main Results:

    • Telithromycin demonstrated comparable efficacy to comparator antibiotics in treating ABS, AECB, and CAP.
    • Treatment durations varied: 5 days for ABS and AECB, 7-10 days for CAP.
    • The most frequent adverse events were mild-to-moderate diarrhea and nausea, occurring slightly more often than in comparator groups.

    Conclusions:

    • Telithromycin is an effective therapeutic option for ABS, AECB, and CAP.
    • Its efficacy is comparable to standard treatments, offering a convenient once-daily dosing regimen.
    • Telithromycin is generally well-tolerated, with most side effects being mild and transient.